Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
Kevin Kalinsky(Emory University), Seth A. Wander(Harvard University), Peter A. Kaufman(University of Vermont), Bastien Nguyen(Eli Lilly (United States)), Holly Knoderer(Eli Lilly (United States)), Kyong Hwa Park(Korea University), Yanhong Zhou(Eli Lilly (United States)), Giampaolo Bianchini(Vita-Salute San Raffaele University), Rinath Jeselsohn(Dana-Farber Cancer Institute), Ling‐Ming Tseng(National Yang Ming Chiao Tung University), Stephanie L. Graff(Providence College), Umut Demırcı(Üsküdar University), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Sara A. Hurvitz(University of Washington), Lacey M. Litchfield(Eli Lilly (United States)), Elizabeth E. Ravenberg(Eli Lilly (United States)), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Erika Hamilton(Sarah Cannon), Miguel Martín(Hospital General Universitario Gregorio Marañón), Sarah Sammons(Dana-Farber Cancer Institute)
Cited by 75
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k